Photo: Callista Images/Getty
Triple-negative breast cancer (TNBC), one the most aggressive forms of the disease, doesn鈥檛 respond well to standard treatments. The U.S. Food and Drug Administration (FDA) recently approved the immunotherapy pembrolizumab (Keytruda庐) for the treatment of early-stage TNBC. Sylvia Adams, MD, professor in the and director of the Breast Cancer Center at 嘿嘿视频 Health鈥檚 Perlmutter Cancer Center, who was among the investigators involved in the pembrolizumab clinical trials, notes that preventing metastatic TNBC, which is difficult to treat, is crucial.
鈥淚t changes the standard of care and should be discussed with all patients who are diagnosed with stage 2 to 3 TNBC,鈥 Dr. Adams says. 鈥淵es, it鈥檚 a game changer, though there is much more to be learned.鈥
Read more from .
